AQILION AB is moving to the new Prisma office building in the Oceanhamnen neighborhood of Helsingborg. The new urban icon will be completed late this fall and Aqilion will move in to its new premises…
AQILION AB is initiating Polaris, a project aimed at developing new drug candidates, the first in their class, to prevent the harmful effects of chronic inflammation. The project will be run in close…
AQILION AB and Immunscape AB initiated a joint early project in oncology and autoimmune diseases in the spring of 2019. The point of departure was to create a drug candidate that the parties would…
AQILION AB announces TAK1 as the target of the internal drug discovery program Alnitak and will present data from the discovery phase at the international partnering event BIO-Europe® 2020 Digital…
Helsingborg, Sweden – June 10, 2020 – AQILION AB held its Annual General Meeting today on June 10, 2020, during which the Meeting resolved in accordance with the proposals set forth by the Board…
Helsingborg, Sweden – May 15, 2020 – AQILION AB announces today that the Annual Report for 2019 is now available in Swedish on the Company’s website. The report summarizes the Company’s…
Helsingborg, Sweden – May 11, 2020 – AQILION AB announced today that Torgeir Vaage has joined the company as Chief Financial Officer (CFO). Torgeir will be responsible for the finance department…
Aqilion opens a branch office at Medicon Village in Lund in order to more efficiently work and integrate with its new partners. The office also provides Aqilion with a local presence and expedites collaborative efforts with the university and the infrastructure that Lund offers a life science company.
Just before the holidays, the Swedish government published its new life science strategy. It describes eight prioritized areas that will strengthen the industry and contribute to Sweden’s…